A Neoadjuvant Phase II Trial of Aromatase Inhibitors in Combination With Everolimus in Postmenopausal Women With Hormone Receptor Positive/HER2 Negative Breast Cancers With Low and Intermediate Risk (< 25) Oncotype Dx Recurrence Scores
Phase of Trial: Phase II
Latest Information Update: 11 Oct 2019
Price : $35 *
At a glance
- Drugs Anastrozole (Primary) ; Aromatase inhibitors (Primary) ; Everolimus (Primary) ; Exemestane (Primary) ; Letrozole (Primary)
- Indications Advanced breast cancer; Carcinoma; Early breast cancer
- Focus Therapeutic Use
- 08 Oct 2019 Planned End Date changed from 1 Sep 2018 to 1 Dec 2020.
- 08 Oct 2019 Planned primary completion date changed from 1 Jan 2018 to 1 Jul 2020.
- 08 Oct 2019 Status changed from completed to suspended.